[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Unusual Options Activity Points to Boston Scientific Stock as a Hot M&A Target

The Montreal Canadiens play the Carolina Hurricanes in Game 5 of the NHL’s Eastern Conference final tonight in Raleigh. Down 3-1, I don’t hold out much hope for the sole remaining Canadian team in this year’s playoffs. 

Hopefully, they win tonight in Carolina and Sunday in Montreal, forcing a Game 7, Montreal’s third consecutive seven-game series. We’ll see. 

Fundamentals

See More
  • Market Capitalization, $K 555,585,728
  • Shares Outstanding, K 2,407,217
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 23,115 M
  • EBITDA $ 30,618 M
  • 60-Month Beta 0.27
  • Price/Sales 5.91
  • Price/Cash Flow 16.38
  • Price/Book 6.86

Options Overview Details

View History
  • Implied Volatility 23.37% (+0.83%)
  • Historical Volatility 19.37%
  • IV Percentile 86%
  • IV Rank 62.64%
  • IV High 29.89% on 03/27/26
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 7) 4.11 (1.83%)
  • Put/Call Vol Ratio 0.94
  • Today's Volume 21,934
  • Volume Avg (30-Day) 21,677
  • Put/Call OI Ratio 0.89
  • Today's Open Interest 346,033
  • Open Int (30-Day) 347,069
  • Expected Range 221.22 to 229.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.83
  • Number of Estimates 8
  • High Estimate $2.88
  • Low Estimate $2.69
  • Prior Year $2.77
  • Growth Rate Est. (year over year) +2.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
220.37 +2.25%
on 05/11/26
235.49 -4.32%
on 05/22/26
-2.02 (-0.89%)
since 04/29/26
3-Month
220.37 +2.25%
on 05/11/26
251.71 -10.48%
on 03/02/26
-23.10 (-9.30%)
since 02/27/26
52-Week
149.04 +51.19%
on 06/20/25
251.71 -10.48%
on 03/02/26
+72.90 (+47.83%)
since 05/28/25

Most Recent Stories

More News
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

CHICAGO , May 29, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 1/1b CHRYSALIS-2 study evaluating intravenous RYBREVANT ® (amivantamab-vmjw)...

JNJ : 225.33 (-2.37%)
Unusual Options Activity Points to Boston Scientific Stock as a Hot M&A Target

Boston Scientific posted two of the top three Volume-to-Open Interest ratios during Thursday's trading session, a notable signal often associated with heightened market speculation. This unusual options...

BSX : 48.31 (-1.63%)
JNJ : 225.33 (-2.37%)
AbbVie Stock: Is ABBV Outperforming the Healthcare Sector?

AbbVie has underperformed the healthcare sector, and analysts remain somewhat optimistic about the stock’s outlook.

XLV : 149.47 (-0.93%)
JNJ : 225.33 (-2.37%)
ABBV : 217.72 (-0.42%)
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma

CHICAGO , May 29, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically...

JNJ : 225.33 (-2.37%)
FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage

TREMFYA ® showed significant inhibition of structural joint damage in adults with active psoriatic arthritis

JNJ : 225.33 (-2.37%)
3 Dividend Kings to Buy Now to Replace the Social Security Income You're About to Lose

The Congressional Budget Office (CBO) released a report this year containing one number that should change how every American near retirement thinks about income. Here's 3 dividend stocks to replace that...

KO : 79.01 (-1.74%)
PG : 143.56 (-1.61%)
JNJ : 225.33 (-2.37%)
Is Eli Lilly Stock Outperforming the Nasdaq?

Eli Lilly has outpaced the Nasdaq Composite over the past year, and analysts remain very confident in its longer-term trajectory.

$NASX : 26,972.62 (+0.20%)
JNJ : 225.33 (-2.37%)
LLY : 1,105.00 (-1.93%)
Is Johnson & Johnson Stock Outperforming the Dow?

Johnson & Johnson has outperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.

JNJ : 225.33 (-2.37%)
LLY : 1,105.00 (-1.93%)
$DOWI : 51,032.46 (+0.72%)
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15 th to review second-quarter...

JNJ : 225.33 (-2.37%)
3 Vanguard Dividend Funds for Low-Cost Income

Dividend funds help you diversify while collecting equity income. You can keep more of that income thanks to the low fees on these Vanguard dividend funds.

AAPL : 312.06 (-0.14%)
AVGO : 446.77 (+4.73%)
VHYAX : 47.75 (+0.02%)
JPM : 299.31 (+0.87%)
JNJ : 225.33 (-2.37%)
VYM : 159.19 (+0.55%)
NSRGY : 101.4400 (-0.49%)
HSBC : 93.74 (+0.85%)
VIHAX : 48.40 (-0.45%)
VIG : 234.65 (+0.33%)
XOM : 145.26 (-1.16%)
VYMI : 100.02 (-0.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 236.61
2nd Resistance Point 234.05
1st Resistance Point 229.69
Last Price 225.33
1st Support Level 222.78
2nd Support Level 220.22
3rd Support Level 215.86

See More

52-Week High 251.71
Last Price 225.33
Fibonacci 61.8% 212.49
Fibonacci 50% 200.38
Fibonacci 38.2% 188.26
52-Week Low 149.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.